Baicalein administered in the subacute phase ameliorates ischemia-reperfusion-induced brain injury by reducing neuroinflammation and neuronal damage

• Published in: Biomedicine & pharmacotherapy Vol. 117; p. 109102
• Main Authors: Yang, Shilun, Wang, Haigang, Yang, Yinglin, Wang, Rui, Wang, Yuehua, Wu, Chunfu, Du, Guanhua
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-09-2019; Elsevier
• Subjects: Animals; Apoptosis - drug effects; Baicalein; Brain Injuries - drug therapy; Brain Injuries - metabolism; Brain Ischemia - drug therapy; Brain Ischemia - metabolism; Cerebral ischemia-reperfusion injury; Flavanones - pharmacology; Inflammation - drug therapy; Inflammation - metabolism; Ischemic stroke; Macrophages - drug effects; Macrophages - metabolism; Male; Microglia - drug effects; Microglia - metabolism; Neuroinflammation; Neurons - drug effects; Neurons - metabolism; Neuroprotective Agents - pharmacology; NF-κB signaling; Rats; Rats, Sprague-Dawley; Reperfusion Injury - drug therapy; Reperfusion Injury - metabolism; Signal Transduction - drug effects; CD86; JNK; HRP; c-Rel; PTEN; Ischemic stroke; I/R; NF-κB; STAIR; mNSS; PI3K; ULK; mTOR; MAPKs; PBS; i.g; DAPI; SDS–PAGE; IL-1β; PVDF; VD; IL-6; IκBα; NeuN; IL-18; ROS; ERK; ELISA; Bcl-2; FDA; TTC; CNS; RHD; SD; p38; Atg5; CCA; ECA; tPA; ICA; TBST; Neuroinflammation; MCA; Akt; 2VO; EDTA; ECL; NF-κB signaling; MCAO/R; TNF-α; CD206; Bax; Baicalein; Cerebral ischemia-reperfusion injury; CD68; HE
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2019.109102

[Display omitted]
•Baicalein administered in the subacute phase ameliorated I/R induced brain injury.•Baicalein regulated M1/M2 transformation of microglia/macrophages in I/R injury.•Baicalein blocked the nuclear translocation of NF-κB/p65 in I/R injury.
Ischemic stroke is a cerebrovascular disease with high morbidity, high mortality, and high disability, representing a serious threat to human life and health. Clinically, the extensive injury caused by ischemic stroke results from ischemia-reperfusion (I/R) injury thrombolytic treatment. However, there are few reports on the use of medications in the subacute stage of cerebral I/R. Baicalein (5,6,7-trihydroxyflavone) is a biologically active ingredient extracted from the root of Scutellaria baicalensis Georgi. In the present study, we investigated the therapeutic effect of baicalein administered in the subacute phase of cerebral I/R injury in a rat model of ischemia induced by occlusion of the middle cerebral artery (MCA). Rats were treated daily with baicalein (200 mg/kg, i.g.) in the subacute phase (24 h after reperfusion) for 7 days. The results showed that baicalein significantly reduced neurobehavioral deficits and decreased brain infarct volume from 18.99% to 7.41%. Immunofluorescence analysis of the ischemic penumbra showed that baicalein significantly reduced expression of the M1 marker, cluster of differentiation (CD) 16 and CD86, and increased expression of the M2 marker, CD 163 and CD206, indicating that baicalein inhibited M1 transformation and promoted M2 transformation of microglia/macrophage to inhibit neuroinflammation. Moreover, baicalein suppressed NF-κB signaling by reducing IκBα phosphorylation and nuclear translocation of NF-κB/p65, which decreased the release of the pro-inflammatory factors IL-6, IL-18, and TNF-α. In addition, baicalein reduced phosphorylation of JNK, ERK and p38, which are involved modulation of microglia/macrophage M1/M2 polarization. Western blot analysis of apoptosis- and autophagy-related proteins showed that baicalein increased the Bcl-2/Bax ratio and reduced caspase-3 expression to decrease neuronal apoptosis and ameliorate neuronal loss. Baicalein also decreased the LC3-II/LC3-I ratio and promoted phosphorylation of the PI3K/Akt/mTOR signaling pathway which implied inhibition of autophagy. These observations suggest that baicalein exerts neuroprotective effects by reducing neuroinflammation, apoptosis and autophagy, and protects against cerebral I/R injury in the subacute phase in vivo.